THC May Weaken the Immune System's Ability to Fight Cancer, Mouse Study Finds
In mouse cancer models, THC reduced the effectiveness of PD-1 immunotherapy by suppressing T-cell function through the CB2 receptor, and higher levels of the endocannabinoid anandamide in human cancer patients were associated with worse survival.
Quick Facts
What This Study Found
THC reduced the therapeutic effect of PD-1 checkpoint blockade in tumor-bearing mice. The endocannabinoid anandamide also impaired antitumor immunity. Using a knock-in mouse model, researchers found CNR2 (CB2 receptor) binds to JAK1 and inhibits downstream STAT signaling in T cells, suppressing their cancer-fighting function. In human cancer patients, higher serum anandamide levels correlated with poorer overall survival.
Key Numbers
THC reduced PD-1 blockade therapeutic effect in mice; CNR2 binds JAK1 and inhibits STAT signaling; high serum anandamide associated with poor overall survival in human cancer patients
How They Did This
Preclinical study using multiple mouse tumor models. Tested THC and anandamide effects on PD-1 immunotherapy efficacy. Generated FLAG-tagged Cnr2 knock-in mice to study molecular mechanisms. Measured JAK/STAT signaling in T cells. Analyzed serum anandamide levels in human cancer patient cohort for survival association.
Why This Research Matters
Many cancer patients use cannabis to manage chemotherapy side effects like nausea, often while receiving immunotherapy. This study raises the concern that THC could undermine the very treatment intended to fight their cancer.
The Bigger Picture
Immunotherapy has transformed cancer treatment, but not all patients respond. If cannabinoids suppress the immune response that immunotherapy is trying to boost, this could partly explain treatment failures in cannabis-using patients and would have major implications for supportive care guidelines.
What This Study Doesn't Tell Us
Mouse tumor models do not perfectly replicate human cancer immunology. The human survival data is observational and cannot prove anandamide caused worse outcomes. THC doses in mice may not reflect typical human cannabis use patterns. Study focused on CB2 mechanism but other pathways may also be involved.
Questions This Raises
- ?Should cancer patients receiving immunotherapy avoid cannabis?
- ?Would CBD (which has different receptor interactions) also suppress antitumor immunity?
- ?At what THC exposure level does immunosuppression become clinically relevant?
Trust & Context
- Key Stat:
- THC reduced immunotherapy efficacy
- Evidence Grade:
- Strong mechanistic evidence from multiple mouse models with supporting human observational data, published in a high-impact journal
- Study Age:
- 2022 study
- Original Title:
- Cannabis suppresses antitumor immunity by inhibiting JAK/STAT signaling in T cells through CNR2.
- Published In:
- Signal transduction and targeted therapy, 7(1), 99 (2022)
- Authors:
- Xiong, Xinxin, Chen, Siyu(2), Shen, Jianfei, You, Hua, Yang, Han, Yan, Chao, Fang, Ziqian, Zhang, Jianeng, Cai, Xiuyu, Dong, Xingjun, Kang, Tiebang, Li, Wende, Zhou, Penghui
- Database ID:
- RTHC-04313
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Should cancer patients stop using cannabis during immunotherapy?
This study raises that concern but cannot definitively answer the question for humans. The mouse data showed THC reduced immunotherapy effectiveness, and human data showed an association between endocannabinoid levels and survival, but clinical trials in humans are needed.
Does CBD have the same effect on cancer immunity?
This study did not test CBD. The immunosuppressive mechanism operated through the CB2 receptor and THC specifically. CBD has different receptor interactions, so its effects may differ, but this was not examined here.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04313APA
Xiong, Xinxin; Chen, Siyu; Shen, Jianfei; You, Hua; Yang, Han; Yan, Chao; Fang, Ziqian; Zhang, Jianeng; Cai, Xiuyu; Dong, Xingjun; Kang, Tiebang; Li, Wende; Zhou, Penghui. (2022). Cannabis suppresses antitumor immunity by inhibiting JAK/STAT signaling in T cells through CNR2.. Signal transduction and targeted therapy, 7(1), 99. https://doi.org/10.1038/s41392-022-00918-y
MLA
Xiong, Xinxin, et al. "Cannabis suppresses antitumor immunity by inhibiting JAK/STAT signaling in T cells through CNR2.." Signal transduction and targeted therapy, 2022. https://doi.org/10.1038/s41392-022-00918-y
RethinkTHC
RethinkTHC Research Database. "Cannabis suppresses antitumor immunity by inhibiting JAK/STA..." RTHC-04313. Retrieved from https://rethinkthc.com/research/xiong-2022-cannabis-suppresses-antitumor-immunity
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.